Abstract:The pharmaceutical industry continues to look for ways to reduce drug candidate attrition throughout the drug discovery and development process. A significant cause of attrition is due to safety issues arising either as a result of animal toxicity testing or in the clinical programme itself. A factor in the assessment of safety during early drug development is the pharmacokinetic profile of the compound. This allows safety data to be considered in the light of systemic drug exposure and therefore permits a quantitative assessment. This is particularly applicable when assessing the risk of a new chemical entity (NCE) in relation to safety parameters such as QT interval prolongation, where free plasma concentrations have been shown to be predictive of this property in relation to potency in preclinical testing. Prior to actual human exposure it is therefore important to be able to predict reliably the pharmacokinetic behaviour of an NCE in order to place such safety findings into a quantitative risk context. The emerging science of pharmacogenetics is likely to further our ability to assess the risk of NCEs to populations and individuals due to genetic variance. The drug metabolizing enzyme CYP2D6 has been recognized as providing the potential to result in widely differing systemic drug exposure in the patient population due to polymorphic expression. Further knowledge is likely to add to our understanding of population differences in exposure and response and aid in the identification of risk factors. One potential strategy for improving the effectiveness of the drug discovery process is to obtain clinical pharmacokinetic data more rapidly in order to assess more accurately the potential for both efficacy and safety of an NCE. Whilst procedures and technologies are available that allow this on the microdose scale, it is important that we recognize potential limitations of these approaches in order that they can be applied beneficially.

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition

Entering the era of computationally driven drug development

Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and/or anionic charges). Data review suggests an emerging pattern

An analysis of the physicochemical properties of oral drugs from 2000 to 2022

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Why 90% of clinical drug development fails and how to improve it?

Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction

Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease

PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets

Early clinical drug product shelf-life setting using accelerated predictive stability and metabolite data for impurity qualification: A case study

Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – A Modeling Approach

Validating ADME QSAR Models Using Marketed Drugs

Target-based drug discovery: is something wrong?

In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate

Dynamic Clinical Success Rates for Drugs in the 21st Century

Screening for human ADME/Tox drug properties in drug discovery

The state of the art in secondary pharmacology and its impact on the safety of new medicines

Early Stage Preclinical Formulation Strategies to Alter the Pharmacokinetic Profile of Two Small Molecule Therapeutics

Productivity shortfalls in drug discovery: contributions from the preclinical sciences?